NCT02179970View on ClinicalTrials.gov

To Assess the Safety of Continuous IV Administration of Plerixafor in Patients With Advanced Pancreatic, Ovarian and Colorectal Cancers

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

December 14, 2018

Study Completion Date

December 14, 2018

Conditions
Pancreatic Adenocarcinoma MetastaticOvarian Serous AdenocarcinomaColorectal Cancer Metastatic
Interventions
DRUG

Plerixafor

A continuous 7 day intravenous infusion, starting at a dose of 20 ug/kg/hr, and subsequent dose levels of 40, 80 and 120 ug/kg/hr.

Trial Locations (1)

CB2 0QQ

Addenbrookes Hospital, Cambridge

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

collaborator

Stand Up To Cancer

OTHER

collaborator

CRUK Cambridge Institute

UNKNOWN

collaborator

Lustgarten Foundation

OTHER

collaborator

National Institute for Health Research, United Kingdom

OTHER_GOV

lead

CCTU- Cancer Theme

OTHER

NCT02179970 - To Assess the Safety of Continuous IV Administration of Plerixafor in Patients With Advanced Pancreatic, Ovarian and Colorectal Cancers | Biotech Hunter | Biotech Hunter